Xilio Therapeutics, Inc. (XLO) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Xilio Therapeutics, Inc.'s investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
-2.14
Burn Risk
P/B Ratio
21.23
Weak
WeakModerateStrong
Earnings Yield
-4.68%
Yield Gap
Profitability Health
2025Return on Equity
-99.33%
Weak
WeakModerateStrong
Operating Margin
-95.92%
Weak
WeakModerateStrong
Net Profit Margin
-80.05%
Weak
WeakModerateStrong
Growth Indicators
2025Revenue Growth
589.88%
Strong
WeakModerateStrong
Net Income Growth
39.84%
Strong
WeakModerateStrong
EPS Growth
72.54%
Strong
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
2.58
Strong
WeakModerateStrong
Quick Ratio
2.58
Strong
WeakModerateStrong
Asset Turnover
0.28x
Weak
WeakModerateStrong
Inventory Turnover
-
No data
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
-0.74%
Weak
WeakModerateStrong
EV / Free Cash Flow
-112.23x
Strong
WeakModerateStrong
Net Debt / EBITDA
3.90x
Weak
WeakModerateStrong
Interest Burden (EBT / EBIT)
0.835
Weak
WeakModerateStrong
Return on Invested Capital
-42.09%
Weak
WeakModerateStrong
Cash Conversion Cycle
-708.67 days
Strong
WeakModerateStrong
Fortress screener guardrails
1/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for XLO.
View Financial Statements